CAR-T細胞療法の世界市場の評価：製品別、用途別、エンドユーザー別、地域別、機会、予測（2018年～2032年）

世界のCAR-T細胞療法の市場規模は、2024年の43億2,000万米ドルから2032年に242億9,000万米ドルに達すると予測され、予測期間の2025年～2032年にCAGRで24.11%の成長が見込まれます。キメラ抗原受容体（CAR）T細胞療法市場は、世界中で血液がんの有病率が高まり、より信頼性の高い治療法を発見するための活動が拡大していることから、大きな成長を示しています。承認されたCAR-T細胞療法は、白血病、リンパ腫、骨髄腫のような複数の種類の血液がんに対して大きな有効性を示すことから、これらの治療法に対する注目度は大幅に高まっており、市場の成長をさらに後押ししています。

新たなCAR-T細胞療法に対する承認の増加や、臨床試験中の強固な製品パイプラインも、市場の拡大に重要な役割を果たしています。市場参入企業間の市場アクセスと収益性の向上を目的とした提携やパートナーシップは、過去の期間において市場の重要な促進要因であったことが証明されており、予測期間も同様の結果が予測されます。さらに、規制遵守と新治療法の承認プロセスの合理化に向けたメーカーの活動の増加は、この市場に対する投資家の関心の高まりもあり、市場の成長を期待させます。

当レポートでは、世界のCAR-T細胞療法市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のCAR-T細胞療法市場の見通し（2018年～2032年）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 製品別
  • 用途別
  • エンドユーザー別
  • 地域別
  • 市場シェア分析：企業別（金額）（上位5社とその他 - 2024年）
• 市場マップ分析（2024年）
  • 製品別
  • 用途別
  • エンドユーザー別
  • 地域別

第5章 北米のCAR-T細胞療法市場の見通し（2018年～2032年）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 製品別
  • 用途別
  • エンドユーザー別
  • シェア：国別
• 各国の市場の評価
  • 米国のCAR-T細胞療法市場の見通し（2018年～2032年）
  • カナダ
  • メキシコ

第6章 欧州のCAR-T細胞療法市場の見通し（2018年～2032年）

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• ポーランド

第7章 アジア太平洋のCAR-T細胞療法市場の見通し（2018年～2032年）

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア
• フィリピン

第8章 南米のCAR-T細胞療法市場の見通し（2018年～2032年）

• ブラジル
• アルゼンチン

第9章 中東・アフリカのCAR-T細胞療法市場の見通し（2018年～2032年）

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ
• イスラエル

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

• 市場促進要因
• 市場の課題

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第18章 特許情勢

第19章 ケーススタディ

第20章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • Novartis Pharmaceutical Corporation
  • Bristol-Myers Squibb Company
  • JW Therapeutics (Shanghai) Co., Ltd.
  • Bluebird bio, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Sorrento Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.

第21章 戦略的提言

第22章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 3. Global CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 4. Global CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 5. Global CAR T-cell Therapy Market Share (%), By Region, 2018-2032F
• Figure 6. North America CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 8. North America CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 9. North America CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 10. North America CAR T-cell Therapy Market Share (%), By Country, 2018-2032F
• Figure 11. United States CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 13. United States CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 14. United States CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 15. Canada CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 17. Canada CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 18. Canada CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 19. Mexico CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 21. Mexico CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 22. Mexico CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 23. Europe CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 25. Europe CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 26. Europe CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 27. Europe CAR T-cell Therapy Market Share (%), By Country, 2018-2032F
• Figure 28. Germany CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 30. Germany CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 31. Germany CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 32. France CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 34. France CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 35. France CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 36. Italy CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 38. Italy CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 39. Italy CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 40. United Kingdom CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 42. United Kingdom CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 43. United Kingdom CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 44. Russia CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 46. Russia CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 47. Russia CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 48. Netherlands CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 50. Netherlands CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 51. Netherlands CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 52. Spain CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 54. Spain CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 55. Spain CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 56. Turkey CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 58. Turkey CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 59. Turkey CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 60. Poland CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 62. Poland CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 63. Poland CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 64. South America CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 65. South America CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 66. South America CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 67. South America CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 68. South America CAR T-cell Therapy Market Share (%), By Country, 2018-2032F
• Figure 69. Brazil CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Brazil CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 71. Brazil CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 72. Brazil CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 73. Argentina CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 74. Argentina CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 75. Argentina CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 76. Argentina CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 77. Asia-Pacific CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Asia-Pacific CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 79. Asia-Pacific CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 80. Asia-Pacific CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 81. Asia-Pacific CAR T-cell Therapy Market Share (%), By Country, 2018-2032F
• Figure 82. India CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 83. India CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 84. India CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 85. India CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 86. China CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 87. China CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 88. China CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 89. China CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 90. Japan CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Japan CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 92. Japan CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 93. Japan CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 94. Australia CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 95. Australia CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 96. Australia CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 97. Australia CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 98. Vietnam CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 99. Vietnam CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 100. Vietnam CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 101. Vietnam CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 102. South Korea CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 103. South Korea CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 104. South Korea CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 105. South Korea CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 106. Indonesia CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Indonesia CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 108. Indonesia CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 109. Indonesia CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 110. Philippines CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Philippines CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 112. Philippines CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 113. Philippines CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 114. Middle East & Africa CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 116. Middle East & Africa CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 117. Middle East & Africa CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 118. Middle East & Africa CAR T-cell Therapy Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 121. Saudi Arabia CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 122. Saudi Arabia CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 123. UAE CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 125. UAE CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 126. UAE CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 127. South Africa CAR T-cell Therapy Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa CAR T-cell Therapy Market Share (%), By Product, 2018-2032F
• Figure 129. South Africa CAR T-cell Therapy Market Share (%), By Application, 2018-2032F
• Figure 130. South Africa CAR T-cell Therapy Market Share (%), By End-user, 2018-2032F
• Figure 131. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global CAR T-cell therapy market is projected to witness a CAGR of 24.11% during the forecast period 2025-2032, growing from USD 4.32 billion in 2024 to USD 24.29 billion in 2032. The chimeric antigen receptor (CAR) T-cell therapy market is witnessing significant growth due to the growing prevalence of hematological malignancies across the globe and efforts to find more reliable treatments for them. The significant efficacy of approved CAR T-cell therapies against several types of hematological malignancies like leukemia, lymphoma, and myeloma has significantly drawn attention toward these therapies, further fueling the market's growth.

An increasing number of approvals for new CAR T-cell therapies and a robust pipeline of products undergoing clinical trials are also playing a crucial role in the market's expansion. Collaborations and partnerships among the market participants to increase market access and profitability have proven to be a significant driver for the market during the historical period and are expected to generate similar results over the forecast period. Additionally, regulatory compliance and increasing efforts of the manufacturers for streamlining the approval process of new therapies coupled with the increasing interest of investors in this market seem promising for market's growth.

Increasing Prevalence of Cancer Boosts Market Demand

As the number of cases of cancer increases, the requirement for advanced therapeutic solutions for effectively treating and managing the condition is also on the rise. Hematological malignancies such as leukemia and lymphoma require innovative treatment solutions such as CAR T-cell therapies as they have shown significant success rates for such conditions. Thus, healthcare institutes across the globe are increasingly focusing on introducing such therapies for treating cancer patients. For instance, in January 2025, Safdarjung Hospital in Delhi, India used a CAR T-cell therapy procedure on a patient suffering from non-Hodgkin lymphoma. This marks the first time CAR T-cell therapy has been used in a central government hospital in India for treating cancer that failed to respond to conventional treatment methods.

Rising Approvals from Regulatory Bodies Supports Market Expansion

The increase in regulatory approvals is playing a crucial role in the growth of the market by allowing wider patient access, encouraging research and development, and increasing investor confidence. As different regulatory bodies recognize the potential of CAR T-cell therapies, they are focusing on streamlining and fast tracking the approval processes, boosting the commercial adoption of the therapies and positively influencing the market's expansion.

For instance, in May 2024, the Food and Drug Administration provided accelerated approval to Juno Therapeutics, Inc. for Breyanzi (lisocabtagene maraleucel) for adults with refractory or relapsed follicular lymphoma, that have received prior systemic therapy. The application was granted orphan drug designation and priority review by the regulatory body. The safety and efficacy of the therapy were evaluated in TRANSCEND-FL (NCT04245839), in an open-label, single-arm, Phase 2, multicenter trial in adults with refractory or relapsed follicular lymphoma.

Lymphoma Accounts for Significant Share of the Market

Due to the high prevalence of the condition and the effective nature of the therapy for treating the disease, the segment holds a significant share in the market. According to the estimates of the American Cancer Society, non-Hodgkin lymphoma accounts for approximately 4% of the cancer cases in America. In order to combat the growing threat of the condition, various regulatory and governing bodies across the globe are increasingly focusing on providing approval to CAR T-cell therapies for treating lymphoma. For instance, in February 2025, the National Institute for Health and Care Excellence (NICE) granted approval to a CAR T-cell therapy for adults with large B-cell lymphoma. The treatment significantly improves survival outcomes and delays the progression of the disease. Lisocabtagene maraleucel is recommended for patients whose cancer has relapsed or is refractory within the first year of the first-line chemoimmunotherapy.

North America Region Holds Major Market Share

With high investment in research and development activities, technological advancements by key players, and presence of advanced healthcare infrastructure, North American countries, including the United States and Canada, are expected to dominate the market with the highest value share. The supportive government initiatives for managing blood-related diseases are also supporting the growth of the market in the region.

Meanwhile, the Asia-Pacific is expected to witness the highest growth over the forecast period. Countries such as Japan, China, and South Korea are significantly investing in CAR T-cell therapy research. The strong market presence of leading players also supporting the market's expansion in the region. Additionally, different governments in the region are recognizing the potential of the CAR T-cell therapies and are increasingly funding research projects to encourage their development.

Future Market Scenario (2025 - 2032F)

The market is expected to witness significant growth in the coming years due to advancements in clinical research, expanded clinical indications of therapy, and rising cases of cancer across the globe. The American Cancer Society estimates that the number of cases of cancer will reach 35 million globally by 2050. Thus, the reliance on CAR T-cell therapy is anticipated to increase significantly over the forecast period.

Meanwhile, innovations aimed at simplifying the manufacturing process and reducing the costs associated with CAR T-cell therapy are expected to improve their accessibility. To support such innovations, leading healthcare and biotech companies are increasingly focusing on developing collaborations. Companies are also focusing on automating production processes for streamlining and standardizing CAR T-cell therapy manufacturing processes, with the goal of reducing processing time and labor cost.

Additionally, CAR T-cell therapies are being increasingly studies in combination with other therapeutic solutions to improve their durability and effectiveness, especially in the cases where traditional treatment options have failed to yield significant results over the patient population. Thus, propelling the utilization of CAR T-cell therapies and providing lucrative growth opportunities for the market.

Key Players Landscape and Outlook

The leading players of the market are significantly focusing on research and development activities and supporting the market's growth and expansion. The companies are also focusing on securing fundings to advanced CAT T therapy trials. For instance, in February 2025, Hemogenyx Pharmaceuticals LLC secured funding to advance its CAR-T therapy trials, aimed at next-generation treatments for acute myeloid leukemia (AML). CAR-T therapy involves the engineering of a patient's T-cells to destroy cancer cells, potentially a more effective and less toxic treatment than traditional chemotherapy. The funding will be used to fund Phase I clinical trials, which will test the safety and preliminary efficacy of this groundbreaking therapy. This development is a significant achievement for Hemogenyx in its pursuit of improving the prognosis of AML patients, who currently have low survival rates. Hemogenyx expects that CAR-T therapy will have a significant impact on the treatment and survival of AML patients.

Similarly, in February 2025, Anixa Biosciences, Inc. announced that it, along with Moffitt Cancer Center, had dosed the third cohort of patients in their Phase 1 clinical trial of their novel CAR-T therapy for recurrent ovarian cancer. After a 30-day confirmation period has passed, the fourth cohort will start with an increase in dose. Anixa's CAR-T technology is designed to target the follicle-stimulating hormone receptor (FSHR), expressed preferentially on ovarian cells and tumor vasculature. The trial (NCT05316129) investigates safety and efficacy in women with recurrent ovarian cancer who have undergone numerous previous treatments. A new protocol amendment allows eligible patients to receive a second dose and enrollment to include rare ovarian cancer subtypes. Such efforts are expected to bolster the availability of advanced treatment technologies and provide lucrative growth opportunities for the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global CAR T-cell Therapy Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product
    • 4.2.1.1. Yescarta (axicabtagene ciloleucel)
    • 4.2.1.2. Kymriah (tisagenlecleucel)
    • 4.2.1.3. Abecma (idecabtagene vicleucel)
    • 4.2.1.4. Tecartus (brexucabtagene autoleucel)
    • 4.2.1.5. Breyanzi (lisocabtagene maraleucel)
    • 4.2.1.6. Others
  • 4.2.2. By Application
    • 4.2.2.1. Leukemia
    • 4.2.2.2. Lymphoma
    • 4.2.2.3. Multiple Myeloma
    • 4.2.2.4. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Cancer Care Treatment Centers
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Product
  • 4.3.2. By Application
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. North America CAR T-cell Therapy Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Yescarta (axicabtagene ciloleucel)
    • 5.2.1.2. Kymriah (tisagenlecleucel)
    • 5.2.1.3. Abecma (idecabtagene vicleucel)
    • 5.2.1.4. Tecartus (brexucabtagene autoleucel)
    • 5.2.1.5. Breyanzi (lisocabtagene maraleucel)
    • 5.2.1.6. Others
  • 5.2.2. By Application
    • 5.2.2.1. Leukemia
    • 5.2.2.2. Lymphoma
    • 5.2.2.3. Multiple Myeloma
    • 5.2.2.4. Others
  • 5.2.3. By End-user
    • 5.2.3.1. Hospitals
    • 5.2.3.2. Cancer Care Treatment Centers
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States CAR T-cell Therapy Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Product
        • 5.3.1.2.1.1. Yescarta (axicabtagene ciloleucel)
        • 5.3.1.2.1.2. Kymriah (tisagenlecleucel)
        • 5.3.1.2.1.3. Abecma (idecabtagene vicleucel)
        • 5.3.1.2.1.4. Tecartus (brexucabtagene autoleucel)
        • 5.3.1.2.1.5. Breyanzi (lisocabtagene maraleucel)
        • 5.3.1.2.1.6. Others
      • 5.3.1.2.2. By Application
        • 5.3.1.2.2.1. Leukemia
        • 5.3.1.2.2.2. Lymphoma
        • 5.3.1.2.2.3. Multiple Myeloma
        • 5.3.1.2.2.4. Others
      • 5.3.1.2.3. By End-user
        • 5.3.1.2.3.1. Hospitals
        • 5.3.1.2.3.2. Cancer Care Treatment Centers
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe CAR T-cell Therapy Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific CAR T-cell Therapy Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America CAR T-cell Therapy Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa CAR T-cell Therapy Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Gilead Sciences, Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Janssen Biotech, Inc.
  • 20.3.3. Novartis Pharmaceutical Corporation
  • 20.3.4. Bristol-Myers Squibb Company
  • 20.3.5. JW Therapeutics (Shanghai) Co., Ltd.
  • 20.3.6. Bluebird bio, Inc.
  • 20.3.7. Merck & Co., Inc.
  • 20.3.8. Johnson & Johnson Services, Inc.
  • 20.3.9. Sorrento Therapeutics, Inc.
  • 20.3.10. Sangamo Therapeutics, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer